DGAP-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces H1/2013 record results, raises 2013 Group earnings guidance

Fresenius SE & Co. KGaA / Key word(s): Quarter Results

30.07.2013 06:59

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Fresenius announces H1/2013 record results, raises 2013 Group earnings
guidance

Group sales increased by 8% (9% in constant currency) to EUR9,987 million
(H1/2012: EUR9,236 million). Organic sales growth was 5%. Acquisitions
contributed a further 5%. Divestitures reduced sales growth by 1%.

Group EBIT* increased by 1% (2% in constant currency) to EUR1,448 million
(H1/2012: EUR1,440 million). The EBIT margin of 14.5% (H1/2012: 15.6%) was
impacted by a margin decrease at Fresenius Medical Care as well as the
first-time consolidation of Fenwal. However, Q2/2013 margin of 14.8%
already showed a distinct improvement over Q1/2013 (14.2%).

Group net income** increased by 11% (12% in constant currency) to EUR482
million (H1/2012: EUR434 million). Group net income attributable to
shareholders of Fresenius SE & Co. KGaA including one-time integration
costs for Fenwal was EUR462 million or EUR2.59 per share.

Based on the Group's positive growth prospects for the second half of 2013,
Fresenius raises its full-year earnings guidance. The company now expects
net income*** to increase by 11% to 14% in constant currency. Previously,
Fresenius expected net income growth of 7% to 12% in constant currency. The
company fully confirms its sales guidance. Sales are expected to increase
by 7% to 10% in constant currency.

* 2013 excluding Fenwal integration costs (EUR27 million). 2012 excluding
one-time costs related to the takeover offer to RHÖN-KLINIKUM AG
shareholders (EUR7 million).

** Net income attributable to shareholders of Fresenius SE & Co. KGaA; 2013
excluding Fenwal integration costs (EUR20 million); 2012 excluding a
non-taxable investment gain (EUR34 million) as well as one-time costs
related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR26
million).

*** Net income attributable to shareholders of Fresenius SE & Co. KGaA;
2013 excluding Fenwal integration costs ?(~EUR?50 million pre tax); 2012
excluding a non-taxable investment gain (EUR34 million) and other one-time
costs at Fresenius Medical Care (EUR17 million) as well as one-time costs
related to the takeover offer to RHÖN-KLINIKUM AG shareholders (EUR29
million).

(Financial statements according to U.S. GAAP)

Fresenius SE & Co. KGaA,
represented by Fresenius Management SE,
Board of Management

Bad Homburg v.d.H., July 30, 2013

End of note

---------------------------------------------------------------------------

Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard),
München; Freiverkehr in Berlin, Hamburg, Hannover, Stuttgart;
Terminbörse EUREX

End of Announcement DGAP News-Service

---------------------------------------------------------------------------